Dr. Arash Olyie Naghavi, MD

Dr. Naghavi practices at Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center.

Dr. Naghavi's NPI, 1396002788, was assigned on April 23, 2012. Dr. Naghavi graduated from UTMB Health in 2012. Dr. Naghavi holds Florida license TRN18697.

Dr. Naghavi's primary practice is Moffitt Cancer Hospital, at 12902 Magnolia Dr, Tampa, FL 33612.

Dr. Naghavi's primary practice is Moffitt Cancer Hospital in Tampa, Florida, part of Moffitt Cancer Center. The medical group on file is Moffitt Cancer Center. Dmand AI also links Dr. Naghavi to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Naghavi practices, 2 sites in all. Vendor and product names are available with a free account.

Radiation oncology is Dr. Naghavi's primary specialty in the NPI Registry, under taxonomy code 2085R0001X. Dr. Naghavi is board certified in radiation oncology by the American Board of Radiology. Dr. Naghavi is licensed in Florida.

Dmand AI lists bone cancer radiation, breast cancer radiation, lung cancer radiation and uterine cancer radiation among the conditions Dr. Naghavi treats.

CMS data shows 2,293 Medicare services from Dr. Naghavi across 13 procedure codes in 2024, for 243 Medicare patients. Medicare paid $132,839 for them.

CMS counts 243 Medicare patients who saw Dr. Naghavi in 2024. The largest group is 65 to 74, with 121 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 7% are also on Medicaid. Their average risk score is 2.03, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Naghavi's median patient age at 67, with 43% women.

In 2024, Dr. Naghavi wrote 268 Medicare Part D claims for 95 patients. 92% of them were for generic drugs. CMS names the drug for 208 of them, across 5 drugs with 11 or more claims each, at $4,092 in total drug cost. In 2023, CMS named 121 claims across 5 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Naghavi for performance year 2024, reported as part of a group. Dr. Naghavi accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Naghavi as offering telehealth.

Dmand AI links 70 papers to Dr. Naghavi, published from 2008 to 2025. 2016 was the busiest year, with 7. The most frequent topics are Sarcoma, Lung Neoplasms and Carcinoma, Non-Small-Cell Lung. Dr. Naghavi has published most often in Int J Radiat Oncol Biol Phys. Dr. Naghavi's most frequent co-authors are Kamran Ali Ahmed, MD, Peter A. Johnstone, MD and Louis B. Harrison, MD.

CMS Open Payments shows 20 general payments to Dr. Naghavi from 11 drug and device companies from 2016 to 2024. Food and beverage make up the largest share, 61% of the total. icotec Medical Inc. paid the most, $1,199.

Dr. Naghavi graduated from UTMB Health in 2012.

Dr. Naghavi is in network with 7 carriers, including Excellus BlueCross BlueShield, Elevance and United Healthcare. POS plans come from the most carriers, 5. Check the plan with the practice before a visit.